Comparison
Methylene Blue vs Thymosin Alpha-1
Side-by-side of Methylene Blue and Thymosin Alpha-1. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Methylene Blue
Methylene blue as a nootropic: low-dose cognitive enhancement, mitochondrial electron cycling, brain oxygen uptake, SSRI interaction risk, typical 0.5 to 4 mg.
Thymosin Alpha-1
Thymosin alpha-1 peptide (Zadaxin, thymalfasin): 28-amino-acid TA1 immunomodulator. Dosing, T-cell effects, hepatitis B and HCV adjunct evidence.
Effects at a glance
Methylene Blue
- •FDA approved for methemoglobinemia and ifosfamide-induced encephalopathy
- •Mitochondrial electron-transport support at low doses (0.5 to 4 mg/kg) via cytochrome c shuttle
- •Potent MAO-A inhibitor; serotonin syndrome risk with SSRIs, SNRIs, MAOIs, fentanyl, tramadol, St John's wort
- •Causes harmless blue-green urine and sweat coloration; useful adherence marker
- •G6PD deficiency is an absolute contraindication; can trigger massive hemolysis
- •Cognitive-enhancement evidence is preliminary, mostly preclinical and small fMRI trials
Thymosin Alpha-1
- •28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
- •Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
- •Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
- •Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
- •Standard label dose: 1.6 mg subcutaneously twice weekly
- •Cleanest safety profile in the peptide class with hundreds of regulated trials behind it
Side-by-side
| Attribute | Methylene Blue | Thymosin Alpha-1 |
|---|---|---|
| Category | pharmaceutical | peptide |
| Also known as | Methylthioninium chloride, Provayblue, tetramethylthionine chloride | Talpha1, Ta1, Zadaxin, Thymalfasin |
| Half-life (hr) ↗ | 5.5 | 2 |
| Typical dose (mg) ↗ | 70 | 1.6 |
| Dosing frequency | 1 to 3 times daily for cognitive use; single IV dose for methemoglobinemia | 2x weekly |
| Routes | oral, intravenous | subcutaneous, intramuscular |
| Onset (hr) | 1 | 24 |
| Peak (hr) | 1.5 | 168 |
| Molecular weight | 319.85 | 3108.32 |
| Molecular formula | C16H18ClN3S | C129H215N33O55 |
| Mechanism | Mitochondrial electron carrier at low doses (cytochrome c shuttle to complex IV) and methemoglobin reductase substrate at higher doses; potent MAO-A inhibitor across the dose range. | Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells. |
| Legal status | Prescription (injectable, FDA approved); supplement form (oral) widely available; not scheduled | Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List |
| WADA status | allowed | unknown |
| DEA / Rx | Not scheduled in the US | Rx only via international approval or US compounding (no controlled-substance schedule) |
| Pregnancy | Contraindicated | Not recommended; insufficient data |
| CAS | 61-73-4 | 62304-98-7 |
| PubChem CID | 6099 | 16130571 |
| Wikidata | Q409021 | Q913854 |
Safety profile
Methylene Blue
Common side effects
- blue-green urine and sweat
- skin and oral mucosa staining
- GI upset
- headache
- dizziness
Contraindications
- G6PD deficiency
- pregnancy
- concurrent serotonergic medication
- severe renal impairment
- infants under 6 months
Interactions
- SSRIs and SNRIs: serotonin syndrome, potentially fatal(major)
- MAOIs: additive MAO inhibition, serotonin syndrome risk(major)
- fentanyl, tramadol, meperidine: serotonin syndrome risk(major)
- dextromethorphan: serotonin syndrome risk(major)
- St John's wort: serotonin syndrome risk(major)
- lithium: additive serotonergic risk(major)
Thymosin Alpha-1
Common side effects
- mild injection-site irritation (rare)
- transient mild fatigue (rare)
- occasional headache (rare)
Contraindications
- pregnancy
- lactation
- active organ transplant rejection therapy
- systemic immunosuppression for autoimmune disease (relative)
- severe active autoimmune disease (caution)
Interactions
- interferon-alpha: additive immune effect; used clinically in approved combination protocols(minor)
- calcineurin inhibitors (cyclosporine, tacrolimus): theoretical destabilization of immunosuppression; avoid(major)
- antimetabolites (azathioprine, mycophenolate): theoretical destabilization of immunosuppression; avoid(major)
- vaccine administration: may augment vaccine response in elderly or immunocompromised; coordinate with clinician(minor)
Which Should You Take?
Methylene Blue comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Thymosin Alpha-1 is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Methylene Blue.
- → If your priority is mitochondrial function, pick Methylene Blue.
- → If your priority is immune support, pick Thymosin Alpha-1.
- → If your priority is post-training recovery, pick Thymosin Alpha-1.
Edge case: If you cannot self-administer injections, Methylene Blue is the only oral option in this pair.
Default choice: Methylene Blue. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Thymosin Alpha-1 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Methylene Blue and Thymosin Alpha-1?
Methylene Blue and Thymosin Alpha-1 differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Methylene Blue or Thymosin Alpha-1?
Methylene Blue half-life is 5.5 hours; Thymosin Alpha-1 half-life is 2 hours.
Can you stack Methylene Blue with Thymosin Alpha-1?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper